Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

PubWeight™: 2.86‹?› | Rank: Top 1%

🔗 View Article (PMC 2826761)

Published in Blood on October 30, 2009

Authors

Huining Kang1, I-Ming Chen, Carla S Wilson, Edward J Bedrick, Richard C Harvey, Susan R Atlas, Meenakshi Devidas, Charles G Mullighan, Xuefei Wang, Maurice Murphy, Kerem Ar, Walker Wharton, Michael J Borowitz, W Paul Bowman, Deepa Bhojwani, William L Carroll, Bruce M Camitta, Gregory H Reaman, Malcolm A Smith, James R Downing, Stephen P Hunger, Cheryl L Willman

Author Affiliations

1: University of New Mexico Cancer Center and Departments of Pathology, Internal Medicine, Mathematics and Statistics, and Physics and Astronomy, University of New Mexico, Albuquerque, NM 87131, USA.

Associated clinical trials:

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | NCT00005603

Articles citing this

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol (2012) 5.08

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood (2010) 4.00

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood (2010) 3.66

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50

Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res (2010) 2.25

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2012) 2.09

Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood (2012) 1.66

Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood (2015) 1.60

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood (2012) 1.47

Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. Cancer Cell (2016) 1.44

Metabolic gatekeeper function of B-lymphoid transcription factors. Nature (2017) 1.40

Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer (2012) 1.29

Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2011) 1.25

Bioinspired multivalent DNA network for capture and release of cells. Proc Natl Acad Sci U S A (2012) 1.21

Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J Natl Cancer Inst (2011) 1.18

Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood (2013) 1.08

A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet (2011) 1.07

PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ (2012) 1.01

Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis (2011) 1.00

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood (2013) 0.99

MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol (2013) 0.95

Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol (2013) 0.93

Protectors or Traitors: The Roles of PON2 and PON3 in Atherosclerosis and Cancer. J Lipids (2012) 0.88

Analysis of Patterns of Gene Expression Variation within and between Ethnic Populations in Pediatric B-ALL. Cancer Inform (2013) 0.88

Regulator of myeloid differentiation and function: The secret life of Ikaros. World J Biol Chem (2011) 0.86

Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. Cancer (2016) 0.85

Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia. Oncotarget (2015) 0.84

Deeper, longer phenotyping to accelerate the discovery of the genetic architectures of diseases. Genome Biol (2014) 0.82

Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. Best Pract Res Clin Haematol (2010) 0.82

Mutational landscape of pediatric acute lymphoblastic leukemia. Cancer Res (2016) 0.81

Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL. PLoS One (2011) 0.81

The role of CCN family genes in haematological malignancies. J Cell Commun Signal (2015) 0.81

Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group. J Pathol Clin Res (2015) 0.80

Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents. Invest New Drugs (2010) 0.80

Aurora B Overexpression Causes Aneuploidy and p21Cip1 Repression during Tumor Development. Mol Cell Biol (2015) 0.80

A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia. Oncotarget (2015) 0.80

Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesis. Haematologica (2014) 0.80

Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. J Pediatr Hematol Oncol (2014) 0.79

LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19. Haematologica (2016) 0.78

An autism case history to review the systematic analysis of large-scale data to refine the diagnosis and treatment of neuropsychiatric disorders. Biol Psychiatry (2014) 0.78

NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity. Blood (2015) 0.78

Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Exp Hematol (2016) 0.78

The anti-apoptotic PON2 protein is Wnt/β-catenin-regulated and correlates with radiotherapy resistance in OSCC patients. Oncotarget (2016) 0.77

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia. Clin Med Insights Oncol (2015) 0.77

Inactivation of KLF4 promotes T cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia (2016) 0.76

High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia. J Exp Clin Cancer Res (2016) 0.76

What happens if you pose the wrong questions? J Physiol (2011) 0.76

High expression of connective tissue growth factor accelerates dissemination of leukaemia. Oncogene (2016) 0.76

Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1(+) pre-B ALL. J Exp Med (2017) 0.76

Improving access to novel agents for childhood leukemia. Cancer (2015) 0.76

Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis. J Cancer Res Clin Oncol (2015) 0.76

Integrative Analysis of MicroRNA-Mediated Gene Signatures and Pathways Modulating White Blood Cell Count in Childhood Acute Lymphoblastic Leukemia. Biomark Insights (2017) 0.75

Apoptosis pathway signature for prediction of treatment response and clinical outcome in childhood high risk B-Precursor acute lymphoblastic leukemia. Am J Cancer Res (2015) 0.75

Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia. Oncotarget (2016) 0.75

Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL? Clin Lymphoma Myeloma Leuk (2015) 0.75

Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALL. Part Part Syst Charact (2013) 0.75

Pediatric oncology: Gene-expression profiling is prognostic in ALL cases. Nat Rev Clin Oncol (2010) 0.75

Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget (2017) 0.75

Identification of differentially expressed genes associated with prognosis of B acute lymphoblastic leukemia. Dis Markers (2015) 0.75

Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia. Sci Rep (2016) 0.75

Articles cited by this

Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83

Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00

Acute lymphoblastic leukaemia. Lancet (2008) 8.54

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood (2008) 5.49

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09

JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98

Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med (1998) 4.39

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood (2006) 3.91

A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells (2007) 3.62

Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst (2006) 2.79

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood (2008) 2.63

A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci U S A (2006) 2.60

Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51

Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med (2007) 2.38

A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19

New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov (2007) 2.09

Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet (2003) 1.79

Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation (2007) 1.70

Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell (2005) 1.58

Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.53

Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol (2007) 1.47

Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood (2007) 1.46

In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med (2008) 1.37

CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci (2007) 1.33

Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol (2007) 1.32

Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. J Natl Cancer Inst (2006) 1.28

The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. Cancer (2008) 1.16

RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood (2004) 1.15

siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene (2006) 1.05

Differential expression of regulator of G-protein signalling transcripts and in vivo migration of CD4+ naïve and regulatory T cells. Immunology (2005) 0.99

CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis. J Immunol (2008) 0.99

High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia. Br J Haematol (2007) 0.95

TTYH2, a human homologue of the Drosophila melanogaster gene tweety, is located on 17q24 and upregulated in renal cell carcinoma. Genomics (2001) 0.93

Isolation of large numbers of mesenchymal stem cells from the washings of bone marrow collection bags: characterization of fresh mesenchymal stem cells. Transplantation (2007) 0.92

Gene expression overlap affects karyotype prediction in pediatric acute lymphoblastic leukemia. Leukemia (2007) 0.91

Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index. Br J Haematol (2008) 0.90

Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol (2007) 0.87

TTYH2, a human homologue of the Drosophila melanogaster gene tweety, is up-regulated in colon carcinoma and involved in cell proliferation and cell aggregation. World J Gastroenterol (2007) 0.85

Articles by these authors

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03

Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64

Age and acute myeloid leukemia. Blood (2006) 6.46

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood (2008) 5.49

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34

The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28

Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20

Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol (2010) 5.11

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol (2012) 5.08

A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02

JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88

Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82

The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70

Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54

Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol (2011) 4.34